Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of NGM/EE Tablets (Wet vs Dry Process)
NCT02127593Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of norgestimate + ethinyl estradiol in pregnancy (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Jun 2013; status: completed.
02
Drugs
norgestimate + ethinyl estradiol
03
Conditions
pregnancy
Beyond the preview
Go deeper on NCT02127593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127593.